

Uterine serosa (Core)

Documentation of the presence or absence of serosal involvement is a core element. According to European Society of Gynaecological Oncology (ESGO)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Pathology (ESP)¹ and International Society of Gynecological Pathologists guidelines,² tumour infiltrating the full myometrial thickness and reaching submesothelial fibroconnective tissue or the mesothelial layer should be reported as serosal involvement. Tumour may or may not be present on the surface of the uterus and a desmoplastic response may or may not be present. *It should be noted that, when present, a desmoplastic stromal reaction can obscure evaluation of the serosa.* Locating the serosal plane flanking the area in question and extending the plane through the area of desmoplasia can be helpful. Serosal involvement is considered present if there is disruption of that plane or carcinoma extends beyond the plane. Involvement of the serosa (International Federation of Gynaecology and Obstetrics (FIGO) Stage IIIA) carries a higher risk of locoregional recurrence than does adnexal involvement (also FIGO Stage IIIA).³

References

- 1 Concin N, Creutzberg CL, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann JA, Bosse T, Chargari C, Fagotti A, Fotopoulou C, González-Martín A, Lax SF, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell DE, Querleu D, Raspollini MR, Sehouli J, Sturdza AE, Taylor A, Westermann AM, Wimberger P, Colombo N, Planchamp F and Matias-Guiu X (2021). ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. *Virchows Arch*:DOI: 10.1007/s00428-00020-03007-z.
- 2 Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R, Euscher E, Hecht JL, Horn LC, Ioffe O, Matias-Guiu X, McCluggage WG, Mikami Y, Ordi J, Parkash V, Quddus MR, Quick CM, Staebler A, Zaloudek C, Nucci M, Malpica A and Oliva E (2019). Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). *Int J Gynecol Pathol* 38 Suppl 1(Iss 1 Suppl 1):S93-s113.
- 3 Jobsen JJ, Naudin Ten Cate L, Lybeert ML, Scholten A, van der Steen-Banasik EM, van der Palen J, Stenfert Kroese MC, Slot A, Schutter EM and Siesling S (2011). Outcome of endometrial cancer Stage IIIA with adnexa or serosal involvement only. *Obstet Gynecol Int* 2011:962518.